CTOs on the Move

BioCryst Pharmaceuticals, Inc.

www.biocryst.com

 
BioCryst Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.biocryst.com
  • 4505 Emperor Blvd Ste 200
    Durham, NC USA 27703
  • Phone: 919.859.1302

Executives

Name Title Contact Details

Funding

BioCryst Pharmaceuticals, Inc. raised $100M on 02/07/2019
BioCryst Pharmaceuticals, Inc. raised $63M on 11/19/2019
BioCryst Pharmaceuticals, Inc. raised $325M on 12/07/2020

Similar Companies

Mcnan Technologies Inc

Mcnan Technologies Inc is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AlgiKnit

AlgiKnit is a collective of designers and scientists who work across disciplines to create new material possibilities. Were creating sustainable, algae-derived, biodegradable yarns and textiles to remediate harmful cycles of fast fashion. Bui...

Targeted Genetics Corporation

Targeted Genetics Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RareCyte

RareCyte is a company focused on characterizing and isolating rare cells from blood.

Cerus

Cerus Corporation is dedicated solely to safeguarding the world`s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.